Thisphenomenon, known as the ‘incretin effect’ (Nauckand Meier, 2018), is impaired in metabolic disorders, such as type 2diabetes mellitus (Holst et al., 2009),making GLP-1 signaling an attractive therapeutic target for the treatment of thesedisorders. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.